

Supplemental Table 1. Characteristics of ACTIVEExtend Participants Aged ≥ 80 Years at ACTIVE Baseline (ITT Population)

Characteristics	Abaloparatide/Alendronate ^a	Placebo/Alendronate ^b
	≥ 80 yr (n = 29)	≥ 80 yr (n = 27)
Age in years, mean (SD)	81.8 (1.5)	81.8 (1.6)
BMI, mean (SD)	25.2 (2.8)	25.5 (3.5)
Years since menopause, mean (SD)	33.1 (4.8)	31.3 (4.3)
Race n (%)		
White	18 (62.1)	16 (59.3)
Asian	9 (31.0)	9 (33.3)
Black or African-American	2 (6.9)	2 (7.4)
Other	0	0
Hispanic or Latino, n (%)	11 (37.9)	10 (37.0)
BMD T-score, mean (SD)		
Lumbar spine	-2.57 (1.42)	-3.03 (0.81)
Total hip	-2.08 (0.70)	-2.39 (0.72)
Femoral neck	-2.39 (0.60)	-2.60 (0.63)
Prevalent vertebral fracture at baseline, n (%) ^c	12 (41.4)	5 (18.5)
At least 1 prior nonvertebral fracture within past 5 years, n (%) ^d	5 (17.2)	5 (18.5)

Note: Participant characteristics taken at baseline from ACTIVE.

BMD, bone mineral density; BMI, body mass index; ITT, intent-to-treat; SD, standard deviation.

^aBaseline characteristics at ACTIVE baseline of participants from the abaloparatide group in ACTIVE who were subsequently treated with alendronate in ACTIVEExtend.

^bBaseline characteristics at ACTIVE baseline of participants from the placebo group in ACTIVE who were subsequently treated with alendronate in ACTIVEExtend.

^cEvaluated by Bioclinica-Synarc.

^dExcluded fractures of the spine, sternum, patella, toes, fingers, skull, and facial bones.